Klin Onkol 2004; 17(6): 196-200.
Summary: Prostate cancer is the most common malignancy in males. Metastatic or osteoporotic bone affections induced by cancer treatment are associated with a significant risk of adverse skeletal complications. Prevention and treatment of skeletal related events (SREs) by zoledronic acid can improve quality of life and effectively prevent and postpone SREs. Zoledronic acid is consider the proigression of safe, well tolerated, and effective in the prophylaxis and treatment of SREs due to prostate cancer. Our first experiences support these findings concerning safety and good tolerability by patients with serious bone affection of prostate cancer.
